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Semaphorin3A Alleviates Skin Lesions and Scratching
Behavior in NC/Nga Mice, an Atopic Dermatitis
Model
Junko Yamaguchi1,2, Fumio Nakamura2, Michiko Aihara1, Naoya Yamashita2, Hiroshi Usui2,
Tomonobu Hida2, Kohtaro Takei2, Yoji Nagashima3, Zenro Ikezawa1 and Yoshio Goshima2
Topical steroids and antihistamines are commonly used for the treatment of atopic dermatitis (AD). However, in
a substantial number of patients with AD, these treatments are not sufficiently effective. In AD patients, C-fibers
in the epidermis increase and sprout, inducing hypersensitivity, which is considered to aggravate the disease.
Semaphorin3A (Sema3A), an axon guidance molecule, is a potent inhibitor of neurite outgrowth of sensory
neurons. To investigate the effect of Sema3A on AD, we administered recombinant Sema3A intracutaneously
into the skin lesions of NC/Nga mice, an animal model of AD. Sema3A dose-dependently improved skin lesions
and attenuated the scratching behavior in NC/Nga mice. Histological examinations revealed a decrease in: (a)
epidermal thickness; (b) the density of invasive nerve fibers in the epidermis; (c) inflammatory infiltrates,
including mast cells and CD4þ Tcells; and (d) the production of IL-4 in the Sema3A-treated lesions. Because the
interruption of the itch–scratch cycle likely contributes to the improvement of the AD-like skin lesions, Sema3A
is promising in the treatment of patients with refractory AD, as well as overall itching dermatosis.
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INTRODUCTION
Atopic dermatitis (AD) is defined as ‘‘an itchy, chronic, or
chronically relapsing, inflammatory skin condition.’’ Because
itch is an unavoidable symptom and markedly reduces
quality of life in AD patients, its control is an important
issue in the treatment of AD. For the treatment of AD, topical
corticosteroids, topical immunosuppressants, and antihista-
mines are commonly used (Friedmann and Holden, 2004).
However, there are a substantial number of AD patients in
whom such medications cannot control the itch sufficiently.
The itch–scratch cycle has attracted attention as a factor in
the aggravation and chronicity of AD (Ikoma et al., 2006;
Paus et al., 2006). Itch is conducted by afferent C-fibers,
which are unmyelinated nerve fibers originating from dorsal
root ganglia neurons. Normally, C-fibers possess free nerve
endings at the boundary between the epidermis and the
dermis, and some nerve fibers invade the epidermis. In AD,
however, C-fibers in the epidermis sprout. This is probably
caused by nerve growth factor (NGF), which is released
from keratinocytes or fibroblasts due to stimulations including
scratching. Semaphorins, a large family of guidance cues for
axonal/dendritic projections, are composed of both secreting
and membrane-bound proteins sharing a sema domain (Luo
et al., 1993; Semaphorin Nomenclature Committee, 1999).
The class 3 subfamily, including semaphorin3A (Sema3A),
are secreted molecules that function as chemorepulsive/
attractive cues in the central and peripheral nervous systems
(Luo et al., 1993; Kolodkin, 1998; Raper, 2000). Neuropilin-1
(NRP-1) binds to Sema3A with high affinity and is necessary
for Sema3A-mediated repulsive guidance events (Nakamura
et al., 1998, 2000; Takahashi et al., 1999; Raper, 2000).
Sema3A potently induces retraction of NGF-sensitive
neurons among dorsal root ganglia neurons (Dontchev and
Letourneau, 2002). The expression levels of NRP-1 are
increased by NGF (Pond et al., 2002). Therefore, it is likely
that Sema3A can induce retraction of invasive nerve fibers in
the epidermis of AD. If it is possible to interrupt the itch–
scratch cycle by use of Sema3A, this may provide the basis
for a novel strategy for the treatment for AD. To investigate
the effects of Sema3A, we locally administered Sema3A to
skin lesions of NC/Nga mouse, which is commonly used as
an AD model. The results showed a marked effect of Sema3A
to reduce the scratch behavior and improve AD-like lesions
both macroscopically and histologically in the NC/Nga mice.
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Histological examination revealed a reduction of the invasive
nerve fibers in the epidermis and a decrease in the infiltration
of inflammatory cells and IL-4 production in the dermis.
Thus, it is likely that Sema3A exerts the effect through both
neurological and immunological mechanisms.
RESULTS
Sema3A macroscopically improved AD
To investigate the effect of Sema3A on AD, 1.0 ml solution of
Sema3A (750 U) or vehicle control was intracutaneously
injected into the dorsal skin lesion of 12- to 14-week-old NC/
Nga mice. Sema3A was administered to each mouse twice a
day for 5 consecutive days. The mice were observed until 11
days after the first injection, and then skin biopsy was
performed. Lesions were evaluated with clinical skin scores
as described previously (Suto et al., 1999; Takakura et al.,
2005). Macroscopically, the intracutaneous administration of
Sema3A markedly improved the lesions in a time-dependent
fashion, leading to a significant reduction in the clinical skin
score. Sema3A tended to decrease the clinical skin score at day
2, and the score was lowest at day 8 (Figure 1a and b). The
vehicle-control treatment produced no effect on the skin lesions
(Figure 1a and b). The improvement of skin lesions was only
observed in those lesions to which Sema3A was administered
and not elsewhere, for instance, the face or ear, demonstrating
the local action of Sema3A. The effect of Sema3A continued for
more than 6 days after the discontinuation of the treatment
(Figure 1b), and then skin lesions gradually deteriorated after
that. At day 16, the Sema3A-treated group had the same
clinical skin score as the no-treatment and control groups (data
not shown). To investigate whether the effect of Sema3A
depended on the injected dose, we administered different doses
of Sema3A and found that Sema3A reduced the clinical skin
score in a dose-dependent manner (Figure 2).
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Figure 1. Sema3A improves AD-like skin lesions of NC/Nga mice. (a) Sema3A markedly suppressed erythema, scaling, erosion, and crust formation in the skin 8
days after the start of the Sema3A treatment. Sema3A (750 U) was intracutaneously injected into the dorsal skin lesions of NC/Nga mice aged 12–14 weeks. Mice
were administered no treatment, vehicle control, or Sema3A twice a day for 5 consecutive days and then observed for 11 days. (b) The improvement of lesion
was evaluated by the clinical skin score. A decrease in the clinical skin score was observed only in the Sema3A-treated group. The effect of Sema3A was
observed only at the site of Sema3A injection and not elsewhere. The improvement of the skin lesion continued for several days after discontinuation of Sema3A.
Values are mean±SEM (n¼ 6). *Po0.05, **Po0.01, Mann–Whitney U-test, compared with no-treatment and control groups.
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Sema3A treatment suppressed the scratching behavior of
NC/Nga mice
We next investigated the effects of intracutaneous injection
of Sema3A on the scratching behavior and the severity of
AD-like lesions in NC/Nga mice. Twice a day for 5
consecutive days, we administered Sema3A to their dorsal
lesions. On the same experimental groups, we observed the
mouse once a day and counted the number of times the
mouse scratched its dorsal skin lesion for 11 consecutive
days. Sema3A caused a reduction in the number of scratches
at day 3 after the start of administration (Figure 3), which was
accompanied by an improvement of the eruptions (data not
shown). An increase in the scratching behavior of the mice
was again observed immediately after the discontinuation of
the Sema3A injection, followed by a recurrence of eruptions.
The suppression of the scratching behavior in NC/Nga mice
by Sema3A was almost completely reversed to the basal
levels on day 4 after the discontinuation of Sema3A (Figure 3).
Sema3A decreased the invasive nerve fiber count in the
epidermis
To investigate the effect of Sema3A on the density of the
invasive nerve fibers into the skin, we performed immuno-
histochemical examination of the sensory neurons using anti-
PGP9.5 antibody, which recognizes a ubiquitin hydrolase
(McCarthy et al., 1995; Horiuchi et al., 2005), a marker
protein of peripheral nerves. At biopsy on day 11, in NC/Nga
mice, an extensive invasion of the PGP9.5-positive nerve
fibers was observed in the epidermis of the skin lesion.
Sema3A (750 U) treatment decreased the PGP9.5-positive
nerve fiber count per area in the epidermis to a similar level
of the normal skin (Figure 4a). In contrast, the density of
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Figure 2. Sema3A improves the skin lesions in a dose-dependent manner.
Sema3A (75 or 750 U) dose-dependently improved skin lesion in NC/Nga
mice. The administration protocol and lesion evaluation were as described in
Figure 1. No improvement of the skin lesion was observed in the no-treatment
group. Values are mean±SEM (n¼6). *Po0.05, **Po0.01, Mann–Whitney
U-test, compared with no-treatment and control groups. Other details are
described in the legend of Figure 1.
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Figure 3. Sema3A interrupts the scratching behavior of NC/Nga mice.
Sema3A was administered as described in the Materials and methods.
Simultaneously, we counted the number of times the mice scratched on their
dorsal skin lesions for 15 min on 11 consecutive days. Sema3A caused a
decrease in the scratching behavior, which was accompanied by
improvement of skin eruptions. The scratching behavior resumed immediately
after discontinuation of Sema3A treatment, followed by recurrence of the
eruptions. *Po0.05, **Po0.01, Mann–Whitney U-test, when compared with
the value on day 1. The scratching behavior was estimated as a percentage of
the control calculated from the mean value of the corresponding no-treatment
group; for each day, the average values of the no-treatment group were
normalized to 100%. Values are mean±SEM (n¼ 6). Other details are
described in the legend of Figure 1.
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Figure 4. Sema3A decreases the density of invasive nerve fibers in the
epidermis. After the administration of no treatment, vehicle control, or
Sema3A, the skin with and without lesion was subjected to biopsy, fixed, and
stained with PGP9.5 antibody. (a) In the Sema3A group, the density of
invasive nerve fibers in the epidermis decreased to a level similar to that in the
normal skin. In contrast, the densities of the nerve fibers remained high in the
epidermis of the no-treatment and vehicle-control groups. Arrows indicate
immunoreactive nerve fibers. Original magnification  400; Bar¼ 100 mm.
(b) The nerve fiber area was quantified by the imaging software (Image J).
Values are mean±SEM (n¼ 6). *Po0.01, Mann–Whitney U-test, compared
with no-treatment and vehicle control.
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invasive nerve fibers in the epidermis remained high in the
no-treatment and vehicle-control groups (Figure 4b).
Sema3A histologically improved AD
Acanthosis and the infiltration of inflammatory cells includ-
ing lymphocytes, mast cells, and eosinophils are histopatho-
logical changes that occur in the skin lesion of AD patients
and NC/Nga mice (Matsuda et al., 1997; Friedmann and
Holden, 2004). After completion of an 11-day observation
period, lesions of each group were subjected to biopsy, fixed,
and stained with hematoxylin and eosin. A decrease in the
epidermal thickness and in the number of infiltrating cells in
the dermis were observed only in the Sema3A-treated skin
areas (Figure 5a and c). Using toluidine blue staining, we also
observed a significant decrease in the number of infiltrating
mast cells in the dermis (Cerio and Calonje, 2004). Again, the
decrease in the number of infiltrating cells was observed only
in the dermis of the Sema3A-treated skin areas (Figure 5b and
d). These results indicate that histological as well as
macroscopic improvement of AD was achieved by the
intracutaneous administration of Sema3A.
Sema3A suppresses CD4þ T cells infiltration and IL-4
production
Several semaphorins play critical roles in the immune system
(Kikutani and Kumanogoh, 2003; Lepelletier et al., 2007). In
Sema3AControlNo
treatment
Normal
skin
Lesional skin
0
100
200
300
400
500
600
700
*
*
In
filt
ra
te
d 
m
as
t c
el
ls 
(nu
mb
er/
mm
2 )
Sema3AControlNo
treatment
Normal
skin
Lesional skin
150
100
50
0
Th
ic
kn
es
s 
of
 e
pi
de
rm
is 
(μm
) *
*
Sema3AControlSema3AControl
Normal skin No treatment Normal skin No treatment
Figure 5. Sema3A suppresses acanthosis, and lymphocyte and mast cell infiltration in AD-like skin lesions. Mice were administered vehicle control or Sema3A
and were observed for 11 days. The lesion sites of the skin were then subjected to biopsy in each group. (a, c) Hematoxylin-and-eosin staining showed an
improvement of acanthosis and a decrease in the number of invasive lymphocytes in the dermis only in the Sema3A-treated group. (b, d) Toluidine blue staining
showed a significant decrease in the mast cell count in the dermis only in the Sema3A-treated group. The number of infiltrated mast cells in the dermis was
quantified by the imaging software (Image J). Values are mean±SEM (n¼ 6). *Po0.01, Mann–Whitney U-test, compared with no-treatment and control groups.
Original magnification  200; Bar¼ 100 mm.
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particular, Sema3A and NRP-1 are expressed in dendritic
cells, which were generated from monocytes, and T cells
(Tordjman et al., 2002; Lepelletier et al., 2006). To investigate
the effects of Sema3A on skin T cells, we immunostained
CD4þ T cells and IL-4 in the skin. As a result, a decrease in
the number of infiltrating CD4þ T cells and IL-4 production
were observed in Sema3A-treated skin area (Figure 6a–d).
Discussion
We demonstrate for the first time that Sema3A markedly
improves AD in NC/Nga mice, an animal model of AD.
Sema3A acts locally and exerts a continuous effect for a while
even after discontinuation. Histopathological examinations
revealed an improvement of acanthosis and a decrease
of inflammatory infiltrate, including mast cells, and CD4þ
T cells in the dermis in the Sema3A-treated skin area. The
treatment of Sema3A markedly decreased the density of
invasive nerve fibers in the Sema3A-treated area but not
elsewhere on each mouse. Moreover, the physical alteration
was associated with the suppression of scratching behavior in
Sema3A-treated animals. This effect of Sema3A was rever-
sible, because the decrease in scratching behavior returned to
the basal levels immediately after the discontinuation of the
Sema3A, followed by recurrence of lesions. These results
suggest that scratching behavior aggravates AD, and Sema3A
can ameliorate the symptoms of AD by interrupting the
itch–scratch cycle, one cause of aggravation and chronicity of
AD. Quite recently, there has been an interesting report that
epidermal Sema3A levels were decreased in patients with AD
compared with healthy volunteers, concomitant with the
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Figure 6. Sema3A suppresses CD4þ T cells and IL-4 production. To investigate the effects of Sema3A on skin inflammatory infiltrate, we immunostained
CD4þ T cells and IL-4 production. A decrease in the number of infiltrating CD4þ T cells and the area of IL-4 were observed in Sema3A-treated skin
area (a, b, c, d). The areas of the dermis and the IL-4 production were quantified by the imaging software (Image J). Values are mean±SEM (n¼ 6). *Po0.01,
Mann–Whitney U-test, compared with no-treatment and control groups. Original magnification  200; Bar¼ 100 mm.
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increase of epidermal nerve densities (Tominaga et al., 2008).
This result shows a good correlation between epidermal
innervation and Sema3A levels and provides a supportive
evidence for our therapeutic claim. Many drugs have been
developed for the treatment of AD. However, there is no
treatment for AD other than Sema3A that targets the invasive
nerve fibers in the epidermis. Therefore, Sema3A is expected
to be effective even for patients with AD, which is resistant to
such drugs that have other pharmacological actions. Our
finding provides the first example for a potential clinical
application of semaphorins.
Recently, attention has been attracted to the transient
receptor potential vanilloid receptor subtype 1 and capsaicin.
The generally accepted basis for the therapeutic application
of capsaicin to mitigate itch is the well-appreciated desensi-
tizing effect of this vanilloid. However, the most notorious
clinical limitation of capsaicin application might be the
transient receptor potential vanilloid receptor subtype 1-
coupled acute excitation of the sensory C-afferents, which
results in a marked ‘‘hot painful burning’’ sensation (Bı´ro´
et al., 2007). Does the local application of Sema3A cause
such a sensation? Does reduction in innervation density of
thin fibers by Sema3A cause sensory deficits? In our experi-
ments, no apparent abnormalities in antinociceptive response
as well as in general symptoms were observed upon Sema3A
treatment (data not shown). Clearly, answering the above
questions will be required before therapeutic attempts in
humans.
Sema3A, when intracutaneously administered repeatedly,
improved AD lesions on day 2 or 3 after the start of the injec-
tions. The effects of Sema3A may involve other mechanisms
such as regulation of the immune and vascular systems, in
addition to the suppression of the invasive sensory neurons in
the epidermis. In addition, NRP-1 and Sema3A are expressed
in human keratinocytes (Kurschat et al., 2006). The kerati-
nocyte NRP-1 and Sema3A may be relevant to the suppres-
sive effect of Sema3A on acanthosis observed in our present
study. Recent evidence indicates that semaphorins play
diverse roles unrelated to axon guidance, including organo-
genesis, vascularization, and angiogenesis (Kitsukawa et al.,
1995; Behar et al., 1996; Soker et al., 1998). In particular,
attention has been given to the fact that several semaphorins
play critical roles in the immune system (Kikutani and
Kumanogoh, 2003; Lepelletier et al., 2007). Studies have
demonstrated that Sema3A (Delaire et al., 2001; Lepelletier
et al., 2007), Sema3C (Mangasser-Stephan et al., 1997),
Sema4A (Kumanogoh et al., 2002), Sema4D (Bougeret et al.,
1992; He´rold et al., 1995; Hall et al., 1996; Wu et al., 1998;
Kumanogoh et al., 2000, 2002; Delaire et al., 2001;
Watanabe et al., 2001), and Sema7A (Holmes et al., 2002)
function in various phases of immune system. Sema3A
and NRP-1 are expressed in dendritic cells, which were
generated from monocytes, and T cells (Tordjman et al.,
2002; Lepelletier et al., 2006). Consistently, our present study
clearly demonstrated that Sema3A suppressed CD4þ T cells
infiltration and IL-4 production in the dermis of NC/Nga
mice, in which dermatitis is closely associated with excessive
IL-4 production as well as inflammatory cell infiltration in the
dermis (Matsuda et al., 1997). In 2005, Takano et al. reported
that anti-NGF antibodies inhibited the development and
proliferation of skin lesions and epidermal innervation, and
any growth in scratching in the NC/Nga mouse. They also
speculate that anti-NGF antibodies may suppress symptoms
of the mice by blocking response to immune cells. Thus,
Sema3A might be similar to anti-NGF antibodies in that both
the agents have immunological as well as neurological
mechanisms. Anti-NGF antibody, however, may affect the
responsiveness of dorsal root ganglia neurons to Sema3A.
NGF is known to increase the expression levels of NRP-1
(Pond et al., 2002) and to augment the effect of Sema3A to
induce axon repulsion (or growth cone collapse) of dorsal
root ganglia neurons (Messersmith et al., 1995). Therefore,
the combination therapy of Sema3A with anti-NGF antibody
may not be justified for AD. Further studies are required to
elucidate the mechanism of action of Sema3A on AD.
In summary, we demonstrated that Sema3A macroscopi-
cally and histologically improved AD model mice. Sema3A
may be effective for the treatment of patients with refractory
AD, who are resistant to existing drugs. In addition, there are
several skin diseases other than AD in which the itch–scratch
cycle is involved. Sema3A may also prove to be widely
effective against these refractory itching skin diseases.
MATERIALS AND METHODS
Animals
Male NC/Nga mice purchased from SLC (Shizuoka, Japan) were
housed in the standard mouse facility and fed with autoclaved diet
and water. Under conventional conditions for 7 weeks, NC/Nga
mice developed spontaneous skin lesions with diagnostic charac-
teristics of high concentrations of total immunoglobulin E in plasma
and invasion of inflammatory cells into the skin lesions. NC/Nga
mice with severe skin lesions frequently scratched their face, ears,
and dorsal skin with their hind paws. Their long-duration scratching
behavior is one index for evaluating the itching in cases of AD
(Takano et al., 2003). NC/Nga mice with similar levels of skin lesion
were used for each experiment. Each experimental group contained
six mice, and more than three experiments were performed for
each experiment. Throughout the experimental procedures, all
efforts were made to minimize the number of animals used and
their suffering, and the experimental procedures have been approved
by ethical committee of Yokohama City University.
Administration of recombinant Sema3A
Recombinant Sema3A was prepared as described previously
(Goshima et al., 1997; Nakamura et al., 1998). In brief, conditioned
medium containing Sema3A was collected 3–5 days after transfec-
tion and was applied to Talon (Clontech, Palo Alto, CA) column
according to the manufacturer’s instructions. The column was
washed with 20 mM Tris-HCl (pH 7.6) buffer containing 0.5 M NaCl.
The recombinant Sema3A was eluted primarily in the 50 mM
imidazole fraction. Conditioned medium of human embryonic
kidney 293T cells transfected with the empty vector DNA was
processed in parallel, and the column fraction with 50 mM imidazole
was used as a control. The activity of Sema3A was assessed by
growth cone collapse assay using chick dorsal root ganglia neurons,
as described previously (Goshima et al., 1995, 1997). One unit was
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defined as the amount of Sema3A per milliliter that induced growth
cone collapse by 50%. The purified Sema3A was diluted with saline
(1:40 v/v) and 1.0 ml of the solution was administered to the dorsal
skin lesion of the mice twice a day for 5 consecutive days. We could
not find any behavioral changes after the injection of Sem3A
as compared with vehicle control.
Clinical skin score
The dorsal skin of each mouse was photographed before, during,
and after Sema3A treatment. The severity of AD-like dorsal skin
lesion was assessed once a day with the following clinical skin score.
Dorsal lesions were evaluated for four symptoms: erythema/
hemorrhage, edema, excoriation/erosion, and scaling/dryness. Each
symptom was graded from 0 to 3 (none, 0; mild, 1; moderate, 2;
severe, 3). Clinical skin score was defined as the sum of the
individual scores, ranging from 0 to 12 (Suto et al., 1999; Takakura
et al., 2005).
Histology
After treatment with or without Sema3A, the NC/Nga mice were
anaesthetized and tissue samples of the skin from the dorsal surface
were fixed in 10% formalin solution. The samples were embedded in
paraffin by the conventional method, cut into 2-mm-thick sections,
and stained with either hematoxylin and eosin or toluidine blue
(Cerio and Calonje, 2004). Thickness of the epidermis in hema-
toxylin and eosin and cell numbers in toluidine blue (number of
mast cells) were expressed as the mean in five fields per mouse.
The dermal area infiltrated mast cells, and the nerve fiber area in
epidermis were quantified by the imaging software (Image J,
National Institutes of Health, MD).
Immunohistochemistry
Formalin-fixed, paraffin-embedded skin sections were deparaffi-
nized with xylene and graded ethanol. Endogenous peroxidases
were blocked using peroxide for 30 min at room temperature. After
washing with PBS, sections were incubated in normal goat serum for
15 min at 371C. Sections were then incubated at 41C overnight with
polyclonal rabbit antibodies against protein gene-product 9.5
(PGP9.5), a pan-neuronal marker (UltraClone Ltd., Isle of Wight,
UK). PGP9.5 is a member of the ubiquitin C-terminal hydrolase
family and presents as a cytoplasmic protein in peripheral nerves
(McCarthy et al., 1995). PGP9.5 is generally used to visualize nerve
fibers in the skin (Horiuchi et al., 2005). The sections were washed
with PBS and then incubated with biotinylated goat anti-rabbit IgG
antibody for 30 min at 371C. Slides were washed with PBS and then
incubated with avidin-biotinylated peroxidase complex. Peroxidase
activity was visualized using stable diaminobenzidine. Staining was
monitored under a bright-field microscope, and sections were
washed with distilled water to stop the reaction. Sections were then
counterstained with methyl green, washed, and mounted. We
analyzed nerve fiber amount in the epidermis according to the
method employed by Takano et al. (2005), in which the NC/Nga
mice were used. They randomly quantified an area of epidermis and
the area of immunoreactive nerve fibers in the epidermis into five
fields per mouse by imaging software (Image J). The ratio of the nerve
fiber area in the epidermis to the epidermal area was then calculated
(mm2 per 1 mm2 epidermis). For staining of CD4þ T cells and IL-4,
frozen section was used. Briefly, optimal cutting temperature
compound-embedded skin slices were fixed in acetone for 10 min,
incubated with rat monoclonal antibodies against mouse CD4 and
IL-4 (Pharmingen, San Diego, CA), followed by goat anti-rat IgG
conjugated with peroxidase (Jackson, West Grove, PA). Visualiza-
tion of the reaction products was performed with diaminobenzidine.
Sections were then counterstained with methyl green. The number of
infiltrated CD4þ T cells and the area of IL-4 production were
expressed as the mean in five fields per mouse. The areas of the
dermis and the IL-4 production were quantified by the imaging
software (Image J).
Evaluation of the effects of Sema3A on established lesions
and scratching behavior
The scratching behavior was recorded on video once a day for
11 consecutive days. We counted the number of times a mouse
scratched on the dorsal skin lesion within a period of 15 min.
Because the average number of scratches in each mouse varied
daily, the scratching behavior was estimated as the percentage of the
control calculated from the mean value of the no-treatment group.
Statistics
Experimental values are given as means±SEM. The statistical
difference was determined by two-sided Mann–Whitney U-test.
Differences with Po0.05 were considered to be significant.
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